Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension

•HVPG ≥10 mmHg persists 2 years after therapy in 53–65% of patients with HCV-related cirrhosis despite HCV eradication. •Changes in liver stiffness do not correlate with changes in HVPG after a sustained virological response. •Baseline HVPG ≥16 mmHg and ascites identify patients with persistent CSPH and risk of decompensation. Background & Aims Clinically significant portal hypertension (CSPH), defined as a hepatic venous pressure gradient...